Hjorth, Maria <br/><br/>
GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.  [electronic resource] 

 -  Clinical immunology (Orlando, Fla.)  Jan 2011 
 - 117-26 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1521-7035 
<br/><br/><label>Standard No.: </label>10.1016/j.clim.2010.10.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Alum Compounds--administration & dosage<br/>Autoantibodies--blood<br/>CD4-Positive T-Lymphocytes--cytology<br/>Cell Count<br/>Child<br/>Diabetes Mellitus, Type 1--enzymology<br/>Female<br/>Forkhead Transcription Factors--genetics<br/>Gene Expression--genetics<br/>Glutamate Decarboxylase--administration & dosage<br/>Humans<br/>Immunosuppression Therapy--methods<br/>Interferon-gamma--metabolism<br/>Interleukin-2 Receptor alpha Subunit--metabolism<br/>Interleukins--metabolism<br/>Leukocytes, Mononuclear--cytology<br/>Lymphocyte Activation--immunology<br/>Male<br/>T-Lymphocytes, Regulatory--cytology<br/>Th2 Cells--immunology<br/>Transforming Growth Factor beta--genetics<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--metabolism